Loading...
•
Dec 31, 2020
ACADIA Q4 2020 Earnings Report
Acadia delivered strong financial results driven by NUPLAZID sales and made advancements in Phase 3 programs.
Key Takeaways
Acadia Pharmaceuticals reported strong financial results for Q4 2020, driven by robust sales of NUPLAZID. The company is focused on continued growth of NUPLAZID and the potential approval and launch of pimavanserin for dementia-related psychosis in 2021.
NUPLAZID net sales increased by 23% compared to Q4 2019.
Research and development expenses increased compared to the same period in 2019.
Selling, general and administrative expenses increased compared to the same period in 2019.
The FDA approved a label update to allow the NUPLAZID capsule to be sprinkled on certain foods.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia provided net sales guidance for NUPLAZID in Parkinson’s disease psychosis (PDP) of $510 to $550 million. GAAP R&D guidance of $300 to $320 million and GAAP SG&A guidance of $560 to $590 million.
Positive Outlook
- Net sales guidance for NUPLAZID in Parkinson’s disease psychosis (PDP) of $510 to $550 million.
- GAAP R&D guidance of $300 to $320 million reflects the progression of candidates in five clinical indications this year.
- GAAP R&D guidance includes approximately $30 million of share-based compensation expense.
- GAAP SG&A guidance of $560 to $590 million reflects a similar level of investment to 2020 in PDP activities, together with additional investments associated with a potential DRP launch.
- GAAP SG&A guidance includes approximately $60 million of share-based compensation expense.
Challenges Ahead
- As this is the potential launch year for dementia-related psychosis (DRP), the Company is not including revenue projections for DRP in 2021 net sales guidance.